WHITEPAPERS

In recent years, nitrosamine impurities have emerged as one of the most significant quality and safety challenges facing the global pharmaceutical industry.

What happens when a formulation that performs flawlessly in a 5-litre lab mixer is scaled up to a 500-litre production vessel—and <br>why is this delicate transition one of the most critical phases in pharmaceutical development that demands closer attention?

Unlocking new frontiers in pharmaceutical innovation